PRESS RELEASE – SpinChip Secures NOK 43 million in Financing Round

Oslo, Norway, 8 January 2024 — SpinChip Diagnostics ASA (“SpinChip”), a pioneering diagnostics company developing a next-generation point-of-care platform for in vitro diagnostics, today announced the completion of its financing round, successfully securing NOK 43 million in the form of a convertible loan.

ABG Sundal Collier and Carnegie Investment Bank acted as Joint Bookrunners for the financing round, which was well supported by existing shareholders and attracted participation from new investors.

The proceeds from the financing round will be used to further advance SpinChip’s proprietary point-of-care (POC) in vitro diagnostics platform, prepare for a CE mark in 2025, and for general corporate purposes.  

Contact information:

Morten Jurs, Chief Executive Officer
Phone: +47 991 67 922

Hamed Brodersen, Chief Financial Officer
Phone: +47 404 68 110

About SpinChip Diagnostics ASA

Representing the future of point-of-care testing, SpinChip Diagnostics was founded in Norway in 2012. SpinChip’s proprietary platform is focused on in vitro diagnostics (IVD) to develop diagnostic tests for acute and chronic cardiac indications where test results are rapidly needed to provide patients with life-saving treatments. The all-in-one platform is based on unique microfluidic technology in combination with nanotechnology-based ultrasensitive detection , which together can relay test results as accurately as high-sensitive laboratory diagnostic machines within minutes, from only a fraction of a droplet of blood.  

Visit  – Next generation point-of-care diagnostics